Epigenetic hypomethylation in FSHD It's not what you inherit, it's whether it shows
Just as a person's qualifications can provide only a guide to their future job performance in the context of an interview, so with many medical conditions that have a genetic basis: the exact DNA alteration can only be a guide to predicting the severity of clinical expression in each case. It is the degree of expression that can be all-important for someone inheriting the condition, particularly when that expression may vary within a family.
In this issue of Neurology ® , Gaillard et al. 1 present the results of their studies of a relatively rare autosomal dominant condition, facioscapulohumeral muscular dystrophy (FSHD), which has a wide range of severity of clinical expression, both between and within families. For the 90% to 95% of persons whose DNA shows a contracted number of copies of a 3.3-kb DNA repeat unit (D4Z4) at 4q35 on one chromosome 4 (a number that stays constant within each family), there is an established inverse correlation between the number of repeats remaining and the clinical severity, as measured by age at first clinical onset. 2, 3 However, a clinical severity scale as predicted from D4Z4 residual copy number can only be "a broad middle between 2 ends," and with known exceptions. At the "mild end," there is substantial nonpenetrance such that within a family, a substantial proportion of adults with the DNA alteration may be asymptomatic. 4 Gaillard et al. 1 introduce a "tool" that might serve as a measurement to guide prediction of the penetrance and clinical severity of FSHD more directly in individual cases. This tool is based on assessing the epigenetic modification of specific domains within each D4Z4 repeat at 4q35, by measuring their degree of hypomethylation in symptomatic and asymptomatic cases.
FSHD can occur as one of 2 genetic forms. FSHD1, comprising 90% to 95% of cases, is the "D4Z4 contraction-dependent" form in which the number of residual copies of D4Z4 repeats at 4q35 on one chromosome 4 is below a threshold level (#11 repeats). FSHD2 ("contraction-independent"), comprising 5% to 10% of cases, does not require a D4Z4 contraction, but is characterized by hypomethylation of both 4q35 D4Z4 regions, in most cases associated with heterozygous alteration in the SMCHD1 gene on chromosome 18p.
5 FSHD1 does show some hypomethylation at 4q35, but only involving the D4Z4-contracted allele. 6 However, neither D4Z4 contraction nor SMCHD1-associated hypomethylation is sufficient on their own to cause FSHD. In people affected with FSHD, the contracted allele in FSHD1, or one of the hypomethylated alleles in FSHD2, must occur on a "permissive" 4q35 haplotype, thereby enabling expression of a DUX4 gene sequence from within the terminal D4Z4 repeat. 7 Current evidence suggests that expression of the normally repressed DUX4 gene is toxic for muscle cells, 8 either directly or through affecting other gene transcription, but much else remains conjecture.
There is a wide range of severity in FSHD, from children losing ambulation in teenage years, to older adults with only scapulohumeral involvement (where female relatives particularly may exhibit nonpenetrance); furthermore, the contracted D4Z4 "permissive" allele may occur in 1.3% of the general population. 9 Therefore, knowing whether and how hypomethylation, D4Z4 contraction, sex, and age interact in penetrance and severity is invaluable for a better understanding of the pathogenesis of FSHD. Previous inconclusive assessments for epigenetic correlation have looked at severity alone or D4Z4 copy number, measuring the overall hypomethylation at D4Z4 and 4q35. 6 Galliard et al. 1 studied 37 patients with proven FSHD1, 9 with FSHD2, and 20 controls, and included several families with FSHD1, in which some members exhibited nonpenetrance. This allowed comparison of 29 asymptomatic but D4Z4 contraction-positive relatives. Instead of assessing overall D4Z4 hypomethylation, they separately assayed 3 different domains of the D4Z4 repeat unit using 2 different methods for each case: immunoprecipitation of methylated CpGs (MeDIP), and sodium bisulfite sequencing.
They found a strong correlation between the degree of hypomethylation and the presence or absence of clinical symptoms of FSHD (r 5 0.45-0.54; p 5 0.0001), thereby establishing a link between hypomethylation at 4q35 and clinical penetrance in FSHD1. Methylation in the nonpenetrant cases was indistinguishable from controls. The degree of hypomethylation is not coinherited and might result from separate (digenic) inheritance or epigenetic modification. Multivariate analysis did not demonstrate any strong correlation of hypomethylation with age or D4Z4 copy number, but with more nonpenetrant females than males (21 females, 8 males); a possible weaker correlation of hypomethylation with sex may need fuller investigation.
Overall, the results of Galliard et al. implicate FSHD as a disease in which an epigenetic or digenically inherited hypomethylation may have a major role in the phenotypic presentation of the underlying mutation. Their study results invite research into other possible influencing factors, including any variation at SMCHD1, or at any other FSHD2 gene. Cases of potentiation of clinical symptoms in "mild" FSHD1 by coincidental inheritance of an SMCHD1 gene alteration are now reported. 10 Understanding the links between D4Z4 contraction, SMCHD1 mutation, hypomethylation, 4q35 haplotype, DUX4 gene expression, effects on other genes, and consequent clinical manifestation will be fundamental to developing treatments for FSHD1/FSHD2.
For the neurologist/geneticist in clinic, the hypomethylation assay still shows considerable overlap between symptomatic and nonpenetrant cases. However, as well as its role in diagnosing FSHD2, a hypomethylation test may offer (1) improved FSHD1 diagnosis or exclusion in anyone with muscle symptoms who has a borderline D4Z4 contraction (9-11 repeats), and (2) better prediction of future manifestation of the clinical phenotype in a predictive genetic test for a family member.
Moreover, this example of FSHD should serve as encouragement to continue exploring whether epigenetic modification or digenic inheritance is the critical element in development of the phenotype in other neurogenetic disorders without a dynamic mutation that show marked intrafamilial variation in age at onset and clinical severity.
